ADCT — ADC Therapeutics SA Share News
0.000.00%
Last trade - 00:00- $133.55m
- $322.91m
- $81.36m
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million
Brief: ADC Therapeutics Announces Amended Healthcare Royalty Financing Agreement
Brief: Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta
Brief: ADC Therapeutics SA - Selling Shareholders May Offer 14.7 Million Common Shares - SEC Filing
ADC Therapeutics Q3 net income beats analyst expectations
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics SA expected to post a loss of 47 cents a share - Earnings Preview
Brief: Adc Therapeutics Announces $100 Mln Private Placement Extending Expected Cash Runway Into 2028
ADC Therapeutics SA reports results for the quarter ended March 31 - Earnings Summary
ADC Therapeutics SA expected to post a loss of 40 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 40 cents a share - Earnings Preview
ADC Therapeutics SA reports results for the quarter ended December 31 - Earnings Summary
Brief: ADC Therapeutics Q4 Net Income USD -30.727 Million
ADC Therapeutics SA expected to post a loss of 41 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 42 cents a share - Earnings Preview
Brief: Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma